Michael McBride, Benjamin M Witkoff, Shannon C Trotter
Dr. McBride is a dermatology resident with HonorHealth/Affiliated Dermatology in Phoenix, Arizona.
Dr. Witkoff is a resident intern physician from Larkin Community Hospital, Palm Springs Campus in Hialeah, Florida.
J Clin Aesthet Dermatol. 2020 Nov;13(11):19-21. Epub 2020 Nov 1.
Hailey-Hailey (HHD), or benign familial chronic pemphigus disease, is a rare autosomal dominant blistering disorder characterized by recurrent vesicles that erode and macerate into weeping and crusting plaques. HHD has been shown to be resistant to several treatment options. Although not yet approved as a treatment for HHD, recent reports have suggested the use of low-dose naltrexone (LDN) as a successful treatment option for controlling recalcitrant HHD. We present a case of a 50-year-old woman with a 20-year history of biopsy-confirmed HHD with recurrent painful and pruritic vesicles and plaques. The patient developed significant clinical improvement of the cutaneous lesions with LDN treatment after only 26 days of treatment. It is important for dermatologists to consider LDN as a viable treatment option for HHD, especially in recalcitrant patients. We suggest this novel treatment as a rapidly effective option to resistant HHD.
黑利-黑利病（HHD），即良性家族性慢性天疱疮，是一种罕见的常染色体显性遗传性水疱性疾病，其特征为反复出现水疱，水疱破溃后浸渍形成渗出性和结痂性斑块。已证明HHD对多种治疗方案均有抵抗性。尽管低剂量纳曲酮（LDN）尚未被批准用于治疗HHD，但最近的报告表明，LDN可作为控制顽固性HHD的一种成功治疗选择。我们报告一例50岁女性患者，有20年经活检确诊的HHD病史，反复出现疼痛性和瘙痒性水疱及斑块。该患者在接受LDN治疗仅26天后，皮肤损害就有了显著的临床改善。皮肤科医生应将LDN视为HHD的一种可行治疗选择，尤其是对于顽固性患者。我们建议将这种新的治疗方法作为治疗抵抗性HHD的一种快速有效的选择。
